# Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/brief-summary-and-adequate-directions-for-use-disclosing-risk-information-in-consumer-directed-print-advertisements-and-promotional-labeling-for-prescription-drugs/47c1576a-8db7-49fb-8fcc-66e1d013145e > FDA guidance document: Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs. Issue date: August 06, 2015. Get complete insights and analysis. --- ## Details - Title: Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs - Communication Type: Guidance Document - Product Type: drugs - Office Name: Center for Drug Evaluation and Research - Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c - Issue Date: 2015-08-06 - Comment Close Date: 2015-10-05 - Last Changed: 2019-02-09 - Docket Number: FDA-2004-D-0500 ## Related Documents - [Drug Interaction Information in Human Prescription Drug and Biological Product Labeling](https://www.globalkeysolutions.net/guidances/guidance-document/drug-interaction-information-in-human-prescription-drug-and-biological-product-labeling/8bdf2914-581b-4e86-8a13-dacb0ef306c0) - [Considerations in Demonstrating Interchangeability With a Reference Product: Update](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-in-demonstrating-interchangeability-with-a-reference-product-update/f154845a-a15e-4508-a634-dd22f907a286) - [Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products—Recommended Practices](https://www.globalkeysolutions.net/guidances/guidance-document/distributing-scientific-and-medical-publications-on-risk-information-for-approved-prescription-drugs-and-biological-productsrecommended-practices/69e4b507-d287-4a18-8387-90dfb7cd1805)